Location: Endemic Poultry Viral Diseases ResearchTitle: Generation of recombinant Newcastle disease virus expressing the S1 protein of turkey enteric coronavirus for use as a bivalent vaccine Author
|Li, Yufeng - Shandong Poultry Research Institute, China|
Submitted to: Meeting Abstract
Publication Type: Abstract Only
Publication Acceptance Date: 9/19/2018
Publication Date: 9/19/2018
Citation: Li, Y., Day, J.M., Yu, Q. 2018. Generation of recombinant Newcastle disease virus expressing the S1 protein of turkey enteric coronavirus for use as a bivalent vaccine [abstract]. 12th Vaccine Congress in Budapest, Hungry, September 16-19, 2018. Paper No. 2.27.
Technical Abstract: Turkey enteric coronavirus (TCoV) causes a contagious form of enteritis in turkeys, generally recognized in the field by outward signs including diarrhea and decreased weight gain, resulting in severe economic losses for the poultry industry in the US. To date there is no commercial vaccine available to control this economically important disease. In this study, we aimed to develop a Newcastle disease virus (NDV) vectored recombinant vaccine against TCoV disease and Newcastle disease (ND). An infectious clone of an enterotropic NDV vaccine strain, V4, was constructed using In-Fusion cloning techniques. The major antigenic spike glycoprotein S1 subunit of TCoV North Carolina 2012 strain was cloned and inserted into the intergenic region between the P and M genes in the V4 infectious clone. The recombinant virus, rV4/TCoV-S1, was rescued using reverse genetics technology. Biological assessment of this recombinant virus by performing the standard mean death time (MDT) and intracerebral pathogenicity index (ICPI) tests, titration, and sequence analysis showed that rV4/TCoV-S1 maintained lentogenic pathotype with similar growth dynamics, stability, and virus titers in vitro when compared to the parental V4 virus. Expression of TCoV S1 protein in the recombinant virus-infected cells was detected by immunofluorescence assay. The results of the study suggest that the rV4/TCoV-S1 is safe and stable, and warrant for a vaccination/challenge clinical trial in turkeys to evaluate the vaccine efficacy against ND and TCoV disease.